NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - General · USD

AbbVie Inc. (ABBV) Stock Analysis

AbbVie Inc. (ABBV) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

ABBV

$256.46

−$3.75 (−1.44%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABBV with… →

ABBV Key Statistics

As of Sep 4, 2026
Trading
Open
$257.96
Previous Close
$260.21
Day's Range
255.58–258.91
52-Week Range
190.75–267.47
Volume
4.73M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.28
Valuation
Market Cap
$453.19B
P/E Ratio
73.48
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.75
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.37
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.04
EPS (ttm)Profit attributable to each share over the last twelve months.
3.49
Financials (FY)
Revenue (FY)
$61.16B+8.57%
Net Income (FY)
$4.23B−1.22%
Profit marginThe share of revenue left as profit after all costs and taxes.
9.80%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.77B
1-Year Return
+24.14%
Dividend and dates
Dividend
$6.92+2.70%
Ex-Dividend Date
July 15, 2026
Earnings Date
October 29, 2026
Avg Volume
6.40M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ABBV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+14.89%
2025+33.08%
2024+18.86%
2023−0.23%
2022+24.01%
2021+32.43%
2020+27.72%
2019+1.47%
2018−0.96%
2017+60.07%
2016 (partial year)−4.74%

As of September 4, 2026.

ABBV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$61.16B$4.23B6.9%
2024$56.33B$4.28B7.6%
2023$54.32B$4.86B9.0%
2022$58.05B$11.84B20.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$61.16B$42.96B$20.09B$4.23B6.9%
2024$56.33B$39.43B$11.89B$4.28B7.6%
2023$54.32B$33.90B$13.54B$4.86B9.0%
2022$58.05B$40.64B$18.81B$11.84B20.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABBV Dividend History

$6.56+5.8% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$5.193—
2025$6.564+5.8%
2024$6.204+4.7%
2023$5.924+5.0%
YearDividends per sharePaymentsChange
2026 (partial year)$5.193—
2025$6.564+5.8%
2024$6.204+4.7%
2023$5.924+5.0%
2022$5.644+8.5%
2021$5.204+10.2%
2020$4.724+10.3%
2019$4.284+19.2%
2018$3.594+40.2%
2017$2.564+349.1%
2016$0.571—

Most recent payment: $1.73 per share, ex-dividend July 15, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

ABBV Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricABBVDrug Manufacturers - General medianvs median
P/E73.4824.69198% above
P/S ratio7.043.13125% above
Profit margin9.80%8.09%1.7 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values AbbVie Inc. (ABBV) at $453.19B. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 57,000 employees.

The most recent close on file for ABBV is $256.46, dated September 4, 2026. That is −$3.75 (−1.44%) against the previous close. Over the past 52 weeks the price has ranged from $190.75 to $267.47. The latest close sits 34.45% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $61.16B. Against the prior fiscal year total of $56.33B, that is a change of +8.57%. The same year closed with net income of $4.23B. That is −1.22% against the prior fiscal year. The reported profit margin is 9.8%. That is 1.7 percentage points above the Drug Manufacturers - General median of 8.09%. Earnings per share on a trailing basis come to 3.49.

Across the 4 fiscal years on file, revenue moves from $58.05B in 2022 to $61.16B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

ABBV trades at a trailing price-to-earnings ratio of 73.48. That is 197.61% above the Drug Manufacturers - General median of 24.69. The forward P/E on file is 15.75. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.37. Measured against sales, the shares trade at 7.04 times revenue. On price-to-sales that is 124.77% above the Drug Manufacturers - General median of 3.13. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +24.14%. Across 10 years the annualized return works out at +19.68%. Beta against the wider market is reported at 0.28. Daily returns over the trailing 10 years annualize to a volatility of 25.99%.

Growth & Income

ABBV pays a dividend yielding 2.7%. The indicated annual rate is $6.92 a share. The ex-dividend date on file is July 15, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $5.19 a share. The year before, 2025, totalled $6.56 a share.

Across the complete calendar years on file, 2017 returned +60.07% and 2018 returned −0.96%. Of the 9 complete calendar years on file, 7 finished higher. 2026 is still running; the price is +14.89% year to date.

Peer Comparison

AbbVie Inc. (ABBV) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AbbVie Inc. ABBV $453.19B 73.5
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
Merck & Co., Inc. MRK $370.89B 122.2

The Drug Manufacturers - General industry average P/E ratio is 24.7x. AbbVie Inc. trades at a P/E of 73.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B

 AMGN

Amgen Inc.

$236.38B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B

 GILD

Gilead Sciences, Inc.

$187.23B
View all Healthcare stocks →

About AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Visit website →